从技术到策略——2023年胰腺癌治疗热点聚焦  

From technology to strategy-focus on hot issues of pancreatic cancer treatment in 2023

作　　者：刘光年 田孝东[1] 杨尹默[1] LIU Guang-nian;TIAN Xiao-dong;YANG Yin-mo(Department of Hepatobiliary and Pancreatic Surgery,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院肝胆胰外科,北京100034

出　　处：《中国实用外科杂志》2024年第1期74-78,共5页Chinese Journal of Practical Surgery

基　　金：国家重点研发计划项目(No.2021YFA0909900);国家自然科学基金项目(No.81871954,No.82171722,No.82271764);北京市自然科学基金项目(No.7212111)。

摘　　要：胰腺癌在所有消化道肿瘤中预后最差。系统治疗背景下胰腺癌多学科综合诊治模式的开展,对胰腺外科产生了深远影响。外科技术方面进步巨大,手术安全性、切除率显著提高,微创手术逐步成为胰腺外科未来发展的趋势。新辅助治疗日趋普及与规范,逐步成为交界可切除及局部进展期胰腺癌病人的标准化治疗模式。免疫和靶向治疗等相关探索曙光初现,但尚乏敏感靶点,为免疫“冷肿瘤”表现。胰腺癌基础研究亟待突破与转化,生物学认知的深入与正确的肿瘤学评价是指导临床决策与改善胰腺癌病人远期预后的根本路径。Pancreatic cancer has the worst prognosis among all gastrointestinal tumors.The development of multidisciplinary comprehensive diagnostic and treatment models for pancreatic cancer in the context of systemic therapy has had a profound impact on pancreatic surgery.Significant progress has been made in surgical techniques,with notable improvements in surgical safety and resection rates.Minimally invasive surgery is gradually becoming the future trend in pancreatic surgery.Neoadjuvant therapy is becoming increasingly popular and standardized,and are now the standard treatment modalities for patients with borderline resectable and locally advanced pancreatic cancer.The dawn of immune and targeted therapies is emerging,yet sensitive targets are still lacking,characterizing pancreatic cancer as an“immune-cold tumor.”There is an urgent need for breakthroughs and translation in basic research on pancreatic cancer.A deeper understanding of its biology and accurate oncological evaluations are fundamental in guiding clinical decisions and improving long-term prognosis for patients with pancreatic cancer.

关 键 词：胰腺癌 胰十二指肠切除术 新辅助治疗 免疫治疗 分子分型 

分 类 号：R6[医药卫生—外科学]